Potentiation of vaccines against rabies and other lyssavirus infections using new type of adjuvans and investigation of selected bat pathogens in bat population

Increasing of the effectiveness of anti-rabies vaccines with mucosal adjuvants: adjuvant vaccines with squalene (SQE) and Poloxamer 105 and Abil-Care 85 detergents were developed. Tested Squalane-based adjuvant formulations are suitable and effective for mucosal use in combination with an anti-rabies vaccine. Testing of the harmlessness of prepared adjuvant formulations and their non-reactogenicity: a new type of squalene adjuvant (oil-in-water) with β-carotene antioxidant is stable, harmless and with non-reactogenicity. Commercial use of formulations for one-step production of adjuvant: a squalene-based adjuvant with β-carotene antioxidant, which is harmless, with non-reactogenicity, fully metabolizable, and without side effect, was prepared. A new adjuvant vaccine was prepared in one-step, which is effective and with simple manipulation and easily applicable. Epizootiological research in bats populations: the presence of P. destructans and the presence of specific EBL antibodies did not confirm. Microsporidia spp., Encephalitozoon hellem and Enterocytozoon bieneusi were detected from blood samples. Mites from genus Spinturnix, Ixodes verspertilionis, Steatonyssus occidentalis, representatives of the family Nycteribiidae and Ischnopsyllus intermedius were found from ectoparasites. Eimeria eggs and represantatives of the family Hymenolepididae were found in faeces samples. The highest prevalence of parasites was found in Miniopterus schreibersii (90.9%) and Rhinolophus euryale (84.6%).